Bd and co

Advancing the World of Health | BD Products Solutions Administrator Ambulatory Surgery Center Solutions Diagnostic Accuracy and Efficiency Hazardous Drug Safety Integrated Diagnostic Solutions Medication Management Solutions Patient Safety Solutions Sepsis Management Surgical Solutions Targeted Temperature Management Vascular Access Management (VAM) Clinician Ambulatory Surgery Center Solutions Antimicrobial Resistance BD Original Equipment Manufacturing (OEM) Cervical Cancer Screening Portfolio Diagnostic Accuracy and Efficiency Hazardous Drug Safety Integrated Diagnostic Solutions Medication Management Solutions Patient Safety Solutions Sepsis Management Stone Management Surgical Solutions Targeted Temperature Management Vascular Access Management (VAM) Distributor BD Original Equipment Manufacturing (OEM) Drug Development Company Drug Delivery Systems Medical Device Manufacturer BD Original Equipment Manufacturing (OEM) Laboratory Antimicrobial Resistance BD Original Equipment Manufacturing (OEM) Cervical Cancer Screening Portfolio Diagnostic Accuracy and Efficiency Integrated Diagnostic Solutions Patient Safety Solutions Sepsis Management Traditional Microbiology Pharmacy Hazardous Drug Safety Integrated Diagnostic Solutions Patient Safety Solutions Medication Management Solutions Sepsis Management Vascular Access Management (VAM) Surgery Ambulatory Surgery Center Solutions Hernia Repair Solutions Patient Safety Solutions Surgical Solutions Venous technology Knowledge Center Events Literature Training Support About BD Our Company About Us Segments Leadership Ethics and Compliance Cybersecurity at BD About Us Trust Center Bulletins and Patches Disclosure Process Helpful Resources Distributors Distributor List Unique device identifier (UDI) ESG (Environmental, Social, and Governance) Global Health Sustainability Inclusion, Diversity & Equity Social Investing Global External Funding Opportunities Investors Innovation at BD Overview BD Idea Submission Process News, Media and Blogs Policies, Guidelines and Statements Center Quality Recent Mergers and Acquisitions Response to COVID-19 Rapid COVID-19 Testing Tools and Trainings Support Offerings Suppliers Corporate Policies and Expectations Doing Business with BD Global Procurement Supplier Programs Careers United States North America Canada (FR) Canada (EN) Mexico United States South America Argentina Brasil Chile Colombia Europe Belgium (FR) Belgium (NL) Česká republika Denmark Europe Suomi France Deutschland Hebrew Hungary (EN) Hungary (HU) United Kingdom Ireland Italia Nederland Norge Polska Россия España Sverige Schweiz Türkiye United Kingdom Middle East / Africa Middle East, North Africa Africa Asia / Pacific Australia / New Zealand 中国 Greater Asia India Indonesia 日本 Korea Malaysia Philippines Singapore Thailand Vietnam Login United States North America Canada (FR) Canada (EN) Mexico United States South America Argentina Brasil Chile Colombia Europe Belgium (FR) Belgium (NL) Česká republika Denmark Europe Suomi France Deutschland Hebrew Hungary (EN) Hungary (HU) United Kingdom Ireland Italia Nederland Norge Polska Россия España Sverige Schweiz Türkiye United Kingdom Middle East / Africa Middle East, North Africa Africa Asia / Pacific Australia / New Zealand 中国 Greater Asia India Indonesia 日本 Korea Malaysia Philippines Singapore Thailand Vietnam Login The Future of Innovation Discover how BD is innovating to drive better outcomes for patients Learn more Video Player is loading.Play VideoPlayMuteCurrent Time 0:00/Duration 0:00Loaded: 0%Stream Type LIVESeek to live, currently behind liveLIVERemaining Time -0:00 1xPlayback RateChaptersChaptersDescriptionsdescriptions off, selectedCaptionscaptions settings, opens captions settings dialogcaptions off, selectedAudio TrackQuality LevelsPicture-in-PictureFullscreenThis is a modal window.Beginning of dialog window. Escape will cancel and close the window.TextColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentBackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparentWindowColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaqueFont Size50%75%100%125%150%175%200%300%400%Text Edge StyleNoneRaisedDepressedUniformDropshadowFont FamilyProportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall CapsReset restore all settings to the default valuesDoneClose Modal DialogEnd of dialog window.Close Modal DialogThis is a modal window. This modal can be closed by pressing the Escape key or activating the close button. Advancing the world of healthTM See how BD is made for today, tomorrow and for what’s needed next Learn more BD AlarisTM Infusion System Receives FDA 510(k) Clearance BD CEO Shares His Perspective on Milestone Learn more The BD Care Continuum Experience Explore how BD solutions advance care across the patient journey Learn more BD Celebrates Associate Volunteers Volunteer Service Trips advance health equity Watch video The Future of Innovation Discover how BD is innovating to drive better outcomes for patients Learn more Video Player is loading.Play VideoPlayMuteCurrent Time 0:00/Duration 0:00Loaded: 0%Stream Type LIVESeek to live, currently behind liveLIVERemaining Time -0:00 1xPlayback RateChaptersChaptersDescriptionsdescriptions off, selectedCaptionscaptions settings, opens captions settings dialogcaptions off, selectedAudio TrackQuality LevelsPicture-in-PictureFullscreenThis is a modal window.Beginning of dialog window. Escape will cancel and close the window.TextColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentBackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparentWindowColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaqueFont Size50%75%100%125%150%175%200%300%400%Text Edge StyleNoneRaisedDepressedUniformDropshadowFont FamilyProportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall CapsReset restore all settings to the default valuesDoneClose Modal DialogEnd of dialog window.Close Modal DialogThis is a modal window. This modal can be closed by pressing the Escape key or activating the close button. Advancing the world of healthTM See how BD is made for today, tomorrow and for what’s needed next Learn more prev 12345 next SEARCH NEWS BD to Present at the 42nd Annual J.P. Morgan Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday,… Learn More NEWS BD Signs White House – U.S. Department of Health and Human Services Pledge to Reduce Greenhouse Gas Emissions Company Reinforces its Commitment to Achieving Net-Zero Emissions and Supporting Decarbonization Across Operations by Joining Health Sector Climate Pledge FRANKLIN LAKES, N.J. (Dec. 20, 2023) –… Learn More BLOG BD CEO on Hospital at Home Imagine you or a loved one having the ability to receive care from the comfort of home. As healthcare trends continue to shift, the “hospital-at-home” vision is becoming a reality. Learn more Our Portfolio Supporting you across healthcare settings 1234567 Alternate SitesDiagnostic LabResearch LabHospital UnitsAnalytic InsightsPharmacySurgical Suite CHALLENGE Quality standards, cost controls and efficiency BD can help you optimize clinical effectiveness to help drive improvement in patient outcomes Ambulatory Surgery Center Solutions CHALLENGE Poor diagnostic results that can lead to improper diagnoses, delays in treatment or other consequences BD can help you set patients on the right clinical path by optimizing the process from specimen collection through the delivery of lab results Diagnostic accuracy and efficiency CHALLENGE Time to insight, translational research impact BD can help you accelerate science and spearhead discovery with a continuous ecosystem for high-dimensional biology research High-Dimensional Biology CHALLENGE Quality of care, cost efficiency, healthcare worker and patient safety and experience BD can help you address infection risk factors that may lead to a healthcare-associated infection (HAI) Patient Safety Solutions CHALLENGE Data rich but not actionable, optimizing alerting from EMR, prioritization for timely decision making BD can help you identify potential “at-risk” patients, empower clinical intervention, and advance health system insights Advanced Clinical Insights CHALLENGE Efficient inventory management, safe and accurate compounding, reduction of medication errors BD can help you reduce the risk of medication errors while optimizing medication inventory management and clinician productivity Medication Management Solutions CHALLENGE Surgical efficiency, patient safety and outcomes, procedural cost management BD can help you improve surgical outcomes and lower costs Surgical Solutions Careers We are the supporters of the journey to discover your possible We believe that encouraging career evolution is key to our success. That the human element, across our global teams, is what keeps us moving the needle forward. Are you ready to bring your big ideas and big ambitions to BD, and make your contribution to our next innovation? Become a maker of possible with us. Visit our careers website Follow us Quick Links Recalls and Field Actions Careers Cybersecurity Electronic Instructions for Use Events Investors Inclusion, Diversity & Equity Literature Live Chat Support News, Media and Blogs Our Company Ethics and Compliance Support Training Contact us Cookie Preferences Privacy Statement Terms of Use Website Accessibility Your Privacy Rights Limit the use of Sensitive Personal Information © 2023 BD. All rights reserved. BD and the BD Logo are trademarks of Becton, Dickinson and Company. All other trademarks are the property of their respective owners. Request Documents Clear All Please ensure Javascript is enabled for purposes of website accessibility Chat with us Our live chat is available between the hours of 8.30am – 5.00pm EST, Monday – Friday × First name Last name Email Company Phone Service Type Technical Support Customer Support Customer SupportTechnical SupportCustomer Support Topic Veritor information Password reset Return labels BD Medical Package inserts Certificates of Analysis (C of A) Dispatch Status/PM Status Learning Compass Learning CompassVeritor informationPassword resetReturn labelsBD MedicalPackage insertsCertificates of Analysis (C of A)Dispatch Status/PM StatusLearning Compass Chat Now Cancel Company Information :: Becton, Dickinson and Company (BDX) Products Solutions Administrator Ambulatory Surgery Center Solutions Diagnostic Accuracy and Efficiency Hazardous Drug Safety Integrated Diagnostic Solutions Medication Management Solutions Patient Safety Solutions Sepsis Management Surgical Solutions Targeted Temperature Management Vascular Access Management (VAM) Clinician Ambulatory Surgery Center Solutions Antimicrobial Resistance BD Original Equipment Manufacturing (OEM) Cervical Cancer Screening Portfolio Diagnostic Accuracy and Efficiency Hazardous Drug Safety Integrated Diagnostic Solutions Medication Management Solutions Patient Safety Solutions Sepsis Management Stone Management Surgical Solutions Targeted Temperature Management Vascular Access Management (VAM) Distributor BD Original Equipment Manufacturing (OEM) Drug Development Company Drug Delivery Systems Medical Device Manufacturer BD Original Equipment Manufacturing (OEM) Laboratory Antimicrobial Resistance BD Original Equipment Manufacturing (OEM) Cervical Cancer Screening Portfolio Diagnostic Accuracy and Efficiency Integrated Diagnostic Solutions Patient Safety Solutions Sepsis Management Traditional Microbiology Pharmacy Hazardous Drug Safety Integrated Diagnostic Solutions Patient Safety Solutions Medication Management Solutions Sepsis Management Vascular Access Management (VAM) Surgery Ambulatory Surgery Center Solutions Hernia Repair Solutions Patient Safety Solutions Surgical Solutions Venous technology Knowledge Center Events Literature Training Support About BD Our Company About Us Segments Leadership Ethics and Compliance Cybersecurity at BD About Us Trust Center Bulletins and Patches Disclosure Process Helpful Resources Distributors Distributor List Unique device identifier (UDI) ESG (Environmental, Social, and Governance) Global Health Sustainability Social Investing Inclusion, Diversity & Equity Global External Funding Opportunities Investors Innovation at BD Overview BD Idea Submission Process News, Media and Blogs Policies, Guidelines and Statements Center Quality Recent Mergers and Acquisitions Response to COVID-19 Rapid COVID-19 Testing Tools and Trainings Support Offerings Suppliers Corporate Policies and Expectations Doing Business with BD Global Procurement Supplier Programs Careers United States Login Skip to main content Skip to section navigation Skip to footer Products Solutions Administrator Ambulatory Surgery Center Solutions Diagnostic Accuracy and Efficiency Hazardous Drug Safety Medication Management Solutions Patient Safety Solutions Sepsis Management Surgical Solutions Targeted Temperature Management Vascular Access Management (VAM) Clinician Ambulatory Surgery Center Solutions Antimicrobial Resistance BD Original Equipment Manufacturing (OEM) Cervical Cancer Screening Portfolio Diagnostic Accuracy and Efficiency Hazardous Drug Safety Medication Management Solutions Patient Safety Solutions Sepsis Management Stone Management Surgical Solutions Targeted Temperature Management Vascular Access Management (VAM) Distributor BD Original Equipment Manufacturing (OEM) Drug Development Company Drug Delivery Systems Medical Device Manufacturer BD Original Equipment Manufacturing (OEM) Laboratory Antimicrobial Resistance BD Original Equipment Manufacturing (OEM) Cervical Cancer Screening Portfolio Diagnostic Accuracy and Efficiency Patient Safety Solutions Sepsis Management Traditional Microbiology Pharmacy Hazardous Drug Safety Patient Safety Solutions Medication Management Solutions Sepsis Management Vascular Access Management (VAM) Surgery Ambulatory Surgery Center Solutions Hernia Repair Solutions Patient Safety Solutions Surgical Solutions Venous technology Knowledge Center Events Literature Training Support About BD Our Company About Us Segments Leadership Ethics and Compliance Cybersecurity at BD About Us Trust Center Bulletins and Patches Disclosure Process Helpful Resources Distributors Distributor List Unique device identifier (UDI) ESG (Environmental, Social, and Governance) Global Health Sustainability Social Investing Inclusion, Diversity & Equity Global External Funding Opportunities Investors Innovation at BD Overview BD Idea Submission Process News, Media and Blogs Policies, Guidelines and Statements Center Quality Recent Mergers and Acquisitions Response to COVID-19 Rapid COVID-19 Testing Tools and Trainings Support Offerings Suppliers Corporate Policies and Expectations Doing Business with BD Global Procurement Supplier Programs Careers United States North America Canada (FR) Canada (EN) Mexico United States South America Argentina Brasil Chile Colombia Europe Belgium (FR) Belgium (NL) Česká republika Denmark Europe Suomi France Deutschland Hebrew Hungary (EN) Hungary (HU) United Kingdom Ireland Italia Nederland Norge Polska Россия España Sverige Schweiz Türkiye United Kingdom Middle East / Africa Middle East, North Africa Africa Asia / Pacific Australia / New Zealand 中国 Greater Asia India Indonesia 日本 Korea Malaysia Philippines Singapore Thailand Vietnam Login United States North America Canada (FR) Canada (EN) Mexico United States South America Argentina Brasil Chile Colombia Europe Belgium (FR) Belgium (NL) Česká republika Denmark Europe Suomi France Deutschland Hebrew Hungary (EN) Hungary (HU) United Kingdom Ireland Italia Nederland Norge Polska Россия España Sverige Schweiz Türkiye United Kingdom Middle East / Africa Middle East, North Africa Africa Asia / Pacific Australia / New Zealand 中国 Greater Asia India Indonesia 日本 Korea Malaysia Philippines Singapore Thailand Vietnam Close Login Company Information Investors Investors Overview News & Events Overview Press Releases IR Calendar BD Innovates 2024 Annual Meeting of Shareholders Email Alerts Company Info Overview Executive Leadership Annual Reports & Proxy Contacts FAQ Financial Info Overview Financial Results Credit Rating Stock Data Quote and Chart Historical Data Analyst Coverage Stock Split History Dividends SEC Filings Overview All SEC Filings Annual Reports Quarterly Reports Section 16 Filings ESG Governance Overview Board of Directors Governance Documents Contact the Board Reporting Accounting, Internal Accounting Controls or Auditing Matters Company Info Overview Executive Leadership Annual Reports & Proxy Contacts FAQ BD is advancing the world of healthTM️️ For over 125 years, BD has been advancing the world of healthTM by improving medical discovery, diagnostics and the delivery of care. We are a clear category leader, with key platforms in many large, foundational areas of healthcare and the global reach, and scale to address healthcare’s most pressing challenges. We’re investing in our human capital, advancing our culture of inclusion, diversity, and equality while fostering a growth mindset and empowering our associates globally to ensure long-term organizational success. View Executive Leadership View Board of Directors Annual Reports & Proxy View our library of Annual Reports and Proxy Statements. View Annual Reports & Proxy IR Contacts See common investor-related contact information. View IR Contacts Frequently Asked Questions Browse our commonly asked investor-related questions. View FAQs By reading this content you are acknowledging our forward looking statement. Forward Looking Statement The information included on this website and other information provided from time to time through webcasts, conference calls, securities analyst meetings, road show presentations, investor conferences, newsletters and similar events and communications contains forward-looking statements (as defined under Federal securities laws) based on current expectations and assumptions that involve risks and uncertainties. If the risks or uncertainties ever materialize or the assumptions prove incorrect, the results of BD may differ materially from those expressed or implied by such forward-looking statements and assumptions. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,” “may,” “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance (including volume growth, pricing, sales and earnings per share growth, and cash flows) and statements regarding our strategy for growth, future product development, regulatory approvals, competitive position and expenditures. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Many of these risks and uncertainties are beyond the company’s control. For a discussion of certain factors that could cause our actual results to differ from our expectations in any forward-looking statements see our latest Annual Report on Form 10-K and other filings with the SEC. BD expressly disclaims any undertaking to update or revise any forward looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation. Email Alerts Contacts RSS News Feed Sitemap Follow us Quick Links Recalls and Field Actions Careers Cybersecurity Electronic Instructions for Use Events Investors Inclusion, Diversity & Equity Literature Live Chat Support News, Media and Blogs Our Company Ethics and Compliance Support Training ©2023 BD. All rights reserved. BD and the BD Logo are trademarks of Becton, Dickinson and Company. All other trademarks are the property of their respective owners. Contact us Cookie Preferences Privacy Statement Terms of Use Website Accessibility Your Privacy Rights Limit the use of Sensitive Personal Information Becton, Dickinson and Company (BDX) Products Solutions Administrator Ambulatory Surgery Center Solutions Diagnostic Accuracy and Efficiency Hazardous Drug Safety Integrated Diagnostic Solutions Medication Management Solutions Patient Safety Solutions Sepsis Management Surgical Solutions Targeted Temperature Management Vascular Access Management (VAM) Clinician Ambulatory Surgery Center Solutions Antimicrobial Resistance BD Original Equipment Manufacturing (OEM) Cervical Cancer Screening Portfolio Diagnostic Accuracy and Efficiency Hazardous Drug Safety Integrated Diagnostic Solutions Medication Management Solutions Patient Safety Solutions Sepsis Management Stone Management Surgical Solutions Targeted Temperature Management Vascular Access Management (VAM) Distributor BD Original Equipment Manufacturing (OEM) Drug Development Company Drug Delivery Systems Medical Device Manufacturer BD Original Equipment Manufacturing (OEM) Laboratory Antimicrobial Resistance BD Original Equipment Manufacturing (OEM) Cervical Cancer Screening Portfolio Diagnostic Accuracy and Efficiency Integrated Diagnostic Solutions Patient Safety Solutions Sepsis Management Traditional Microbiology Pharmacy Hazardous Drug Safety Integrated Diagnostic Solutions Patient Safety Solutions Medication Management Solutions Sepsis Management Vascular Access Management (VAM) Surgery Ambulatory Surgery Center Solutions Hernia Repair Solutions Patient Safety Solutions Surgical Solutions Venous technology Knowledge Center Events Literature Training Support About BD Our Company About Us Segments Leadership Ethics and Compliance Cybersecurity at BD About Us Trust Center Bulletins and Patches Disclosure Process Helpful Resources Distributors Distributor List Unique device identifier (UDI) ESG (Environmental, Social, and Governance) Global Health Sustainability Social Investing Inclusion, Diversity & Equity Global External Funding Opportunities Investors Innovation at BD Overview BD Idea Submission Process News, Media and Blogs Policies, Guidelines and Statements Center Quality Recent Mergers and Acquisitions Response to COVID-19 Rapid COVID-19 Testing Tools and Trainings Support Offerings Suppliers Corporate Policies and Expectations Doing Business with BD Global Procurement Supplier Programs Careers United States Login Skip to main content Skip to section navigation Skip to footer Products Solutions Administrator Ambulatory Surgery Center Solutions Diagnostic Accuracy and Efficiency Hazardous Drug Safety Medication Management Solutions Patient Safety Solutions Sepsis Management Surgical Solutions Targeted Temperature Management Vascular Access Management (VAM) Clinician Ambulatory Surgery Center Solutions Antimicrobial Resistance BD Original Equipment Manufacturing (OEM) Cervical Cancer Screening Portfolio Diagnostic Accuracy and Efficiency Hazardous Drug Safety Medication Management Solutions Patient Safety Solutions Sepsis Management Stone Management Surgical Solutions Targeted Temperature Management Vascular Access Management (VAM) Distributor BD Original Equipment Manufacturing (OEM) Drug Development Company Drug Delivery Systems Medical Device Manufacturer BD Original Equipment Manufacturing (OEM) Laboratory Antimicrobial Resistance BD Original Equipment Manufacturing (OEM) Cervical Cancer Screening Portfolio Diagnostic Accuracy and Efficiency Patient Safety Solutions Sepsis Management Traditional Microbiology Pharmacy Hazardous Drug Safety Patient Safety Solutions Medication Management Solutions Sepsis Management Vascular Access Management (VAM) Surgery Ambulatory Surgery Center Solutions Hernia Repair Solutions Patient Safety Solutions Surgical Solutions Venous technology Knowledge Center Events Literature Training Support About BD Our Company About Us Segments Leadership Ethics and Compliance Cybersecurity at BD About Us Trust Center Bulletins and Patches Disclosure Process Helpful Resources Distributors Distributor List Unique device identifier (UDI) ESG (Environmental, Social, and Governance) Global Health Sustainability Social Investing Inclusion, Diversity & Equity Global External Funding Opportunities Investors Innovation at BD Overview BD Idea Submission Process News, Media and Blogs Policies, Guidelines and Statements Center Quality Recent Mergers and Acquisitions Response to COVID-19 Rapid COVID-19 Testing Tools and Trainings Support Offerings Suppliers Corporate Policies and Expectations Doing Business with BD Global Procurement Supplier Programs Careers United States North America Canada (FR) Canada (EN) Mexico United States South America Argentina Brasil Chile Colombia Europe Belgium (FR) Belgium (NL) Česká republika Denmark Europe Suomi France Deutschland Hebrew Hungary (EN) Hungary (HU) United Kingdom Ireland Italia Nederland Norge Polska Россия España Sverige Schweiz Türkiye United Kingdom Middle East / Africa Middle East, North Africa Africa Asia / Pacific Australia / New Zealand 中国 Greater Asia India Indonesia 日本 Korea Malaysia Philippines Singapore Thailand Vietnam Login United States North America Canada (FR) Canada (EN) Mexico United States South America Argentina Brasil Chile Colombia Europe Belgium (FR) Belgium (NL) Česká republika Denmark Europe Suomi France Deutschland Hebrew Hungary (EN) Hungary (HU) United Kingdom Ireland Italia Nederland Norge Polska Россия España Sverige Schweiz Türkiye United Kingdom Middle East / Africa Middle East, North Africa Africa Asia / Pacific Australia / New Zealand 中国 Greater Asia India Indonesia 日本 Korea Malaysia Philippines Singapore Thailand Vietnam Close Login BD Innovates Our BD Innovates series provides investors insight on the innovations transforming the future of healthcare. Explore BD Innovates Series Previous Next Investor Relations Alaris Update: FDA 510(k) Clearance Jul 24, 2023 BD CEO Tom Polen Addresses FDA 510(k) Clearance of BD AlarisTM Infusion System Jul 21, 2023 BD Receives FDA 510(k) Clearance for Updated BD AlarisTM Infusion System Previous Next Investors Investors Overview News & Events Overview Press Releases IR Calendar BD Innovates 2024 Annual Meeting of Shareholders Email Alerts Company Info Overview Executive Leadership Annual Reports & Proxy Contacts FAQ Financial Info Overview Financial Results Credit Rating Stock Data Quote and Chart Historical Data Analyst Coverage Stock Split History Dividends SEC Filings Overview All SEC Filings Annual Reports Quarterly Reports Section 16 Filings ESG Governance Overview Board of Directors Governance Documents Contact the Board Reporting Accounting, Internal Accounting Controls or Auditing Matters Stock Information View Detailed Stock Information View Detailed Stock Information Quarterly Earnings Events News Releases SEC Filings ESG About BD BD is a global medical technology company that is advancing the world of healthTM by improving medical discovery, diagnostics and the delivery of care. 77,000+ BD Associates 190+ Countries Served 37B+ Devices Made Annually $1B+ Annual R&D Spending 31,000+ Active Patents As of Jan 24, 2023 • Annual Meeting of Shareholders Presentation For complete information regarding our financials, see our periodic filings Upcoming Event BD at 42nd Annual J.P. Morgan Healthcare Conference Jan 9, 2024 10:30 am EST View Event Add to Calendar View All Events Latest Financial Results Q4 FY23 Fiscal Year Ended Sep 30, 2023 Earnings Release HTML PDF Earnings Webcast Audio Presentation PDF 10-K Filing HTML PDF Annual Report PDF $5.1B Q4 2023 Total BD Revenue $3.42 Q4 2023 Adjusted EPS* Source: Q4 2023 Earning Press Release * Non-GAAP Financial Measures. View full reconciliation in our Q4 earnings press release. For complete information regarding our financials, see our periodic filings Latest Annual Report For Fiscal Year Ending Sep 30, 2023 Report Links Annual Report Document Links View Report View 10-K Email Alerts Sign up today and receive company updates straight to your inbox. Sign Up Today Latest News BD to Present at the 42nd Annual J.P. Morgan Healthcare Conference Dec 22, 2023 7:00 am EST View Press Release BD Signs World Economic Forum’s Zero Health Gaps Pledge Dec 11, 2023 6:55 am EST View Press Release BD Receives FDA 510(k) Clearance for Potentially Transformative Fingertip Blood Collection Device Dec 7, 2023 6:50 am EST View Press Release View All News See How BD Solutions Advance Care Across The Patient Journey Learn More Together We Advance Our ESG strategy—a four-pillar framework called Together We Advance—embraces the connections and interdependence between company health, planet health, community health and human health. Through this framework, we address the most relevant ESG issues for our business and stakeholders. View ESG Efforts Featured Reports 2023 Annual Report Download Report 2022 ESG Report Download Report 2022 Inclusion, Diversity and Equity Report Download Report 2022 Cybersecurity Annual Report Download Report IR Contacts Corporate Office Becton, Dickinson and Company 1 Becton Drive Franklin Lakes, NJ 07417 United States 800.284.6845 Investor Relations Becton, Dickinson and Company 800.284.6845 [email protected] Transfer Agent Computershare Trust Company, N.A. P.O. Box 43006 Providence, RI 02940-3066 877.498.8861 [email protected] https://www.computershare.com Overnight Mail Address 150 Royall St., Suite 101 Canton, MA 02021 By reading this content you are acknowledging our forward looking statement. Forward Looking Statement The information included on this website and other information provided from time to time through webcasts, conference calls, securities analyst meetings, road show presentations, investor conferences, newsletters and similar events and communications contains forward-looking statements (as defined under Federal securities laws) based on current expectations and assumptions that involve risks and uncertainties. If the risks or uncertainties ever materialize or the assumptions prove incorrect, the results of BD may differ materially from those expressed or implied by such forward-looking statements and assumptions. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,” “may,” “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance (including volume growth, pricing, sales and earnings per share growth, and cash flows) and statements regarding our strategy for growth, future product development, regulatory approvals, competitive position and expenditures. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Many of these risks and uncertainties are beyond the company’s control. For a discussion of certain factors that could cause our actual results to differ from our expectations in any forward-looking statements see our latest Annual Report on Form 10-K and other filings with the SEC. BD expressly disclaims any undertaking to update or revise any forward looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation. Email Alerts Contacts RSS News Feed Sitemap Follow us Quick Links Recalls and Field Actions Careers Cybersecurity Electronic Instructions for Use Events Investors Inclusion, Diversity & Equity Literature Live Chat Support News, Media and Blogs Our Company Ethics and Compliance Support Training ©2023 BD. All rights reserved. BD and the BD Logo are trademarks of Becton, Dickinson and Company. All other trademarks are the property of their respective owners. Contact us Cookie Preferences Privacy Statement Terms of Use Website Accessibility Your Privacy Rights Limit the use of Sensitive Personal Information Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use. BD (company) – Wikipedia Jump to content Main menu Main menu move to sidebar hide Navigation Main pageContentsCurrent eventsRandom articleAbout WikipediaContact usDonate Contribute HelpLearn to editCommunity portalRecent changesUpload file Languages Language links are at the top of the page. Search Search Create account Log in Personal tools Create account Log in Pages for logged out editors learn more ContributionsTalk Contents move to sidebar hide (Top) 1History 2Finances 3Business segments Toggle Business segments subsection 3.1BD Medical 3.2BD Life Sciences 3.3BD Interventional 4Environmental and social track record Toggle Environmental and social track record subsection 4.1Health and safety issues 5Recalls Toggle Recalls subsection 5.12007 Discardit II incident in Poland 5.22010 Q-Syte Luer and IV Catheter partial recall 5.32021 IV Giving Sets 6See also 7References 8External links Toggle the table of contents BD (company) 6 languages DeutschفارسیFrançais日本語Русский中文 Edit links ArticleTalk English ReadEditView history Tools Tools move to sidebar hide Actions ReadEditView history General What links hereRelated changesUpload fileSpecial pagesPermanent linkPage informationCite this pageGet shortened URLWikidata item Edit interlanguage links Print/export Download as PDFPrintable version Coordinates: 41°00′57′′N 74°12′36′′W / 41.015834°N 74.210136°W / 41.015834; -74.210136 From Wikipedia, the free encyclopedia Parts of this article (those related to documentation) need to be updated. Please help update this article to reflect recent events or newly available information. (January 2022) American biotechnology Company Becton, Dickinson and CompanyTrade nameBDTypePublicTraded asNYSE: BDXS&P 500 componentIndustryMedical equipment, ConsultingFoundedEast Rutherford, New Jersey (1897 (1897))FounderMaxwell Becton and Fairleigh S. DickinsonHeadquartersBD HeadquartersFranklin Lakes, New Jersey, U.S.Area servedWorldwideKey people Tom Polen[1] (Chairman, CEO and President) Christopher R. Reidy[2] (Executive Vice President and CAO) Christopher DelOrefice[3] (Executive Vice President and CFO) Revenue US$20.248 Billion (Fiscal Year Ended September 30, 2021)[4]Operating income US$2.799 Billion (Fiscal Year Ended September 30, 2021)[4]Net income US$2.002 Billion (Fiscal Year Ended September 30, 2021)[4]Total assets US$53.866 Billion (Fiscal Year Ended September 30, 2021)[4]Total equity US$23.677 Billion (Fiscal Year Ended September 30, 2021)[4]Number of employees75,000 (2021)[4]DivisionsBD Medical; BD Life Sciences; BD InterventionalWebsitebd.com 41°00′57′′N 74°12′36′′W / 41.015834°N 74.210136°W / 41.015834; -74.210136 Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.[citation needed] BD is ranked #177 in the 2021 Fortune 500 list[5] based on its revenues for the fiscal year ending September 30, 2020. In October 2014, the company agreed to acquire CareFusion for a price of US$12.2 billion in cash and stock.[6] In April 2017, C. R. Bard announced that it would be acquired by Becton, Dickinson and Company (BD).[7] The transaction was completed later that year, and the company became a wholly-owned subsidiary of BD, rebranded as Bard. History[edit] The company was founded in 1897 in New York City by Maxwell Becton and Fairleigh S. Dickinson. It later moved its headquarters to New Jersey. In 2004, BD agreed to pay out US$100 million to settle allegations from competitor Retractable Technologies that it had engaged in anti-competitive behavior to prevent the distribution of Retractable’s syringes, which are designed to prevent needlestick injury.[8] The lawsuit touched off a series of legal conflicts between the companies. Retractable would accuse BD of patent infringement after BD released a retractable needle of its own. Later Retractable would claim BD was falsely advertising its own brand of retractable needle as the “world’s sharpest needle”.[9] Finances[edit] For the fiscal year 2017, Becton Dickinson reported earnings of US$1.030 billion, with an annual revenue of US$12.093 billion, an increase of 10.5% over the previous fiscal cycle. Becton Dickinson’s shares traded at over US$192 per share, and its market capitalization was valued at over US$63 billion in November 2018.[10] Year Revenuein mil. USD$ Net incomein mil. USD$ Total Assetsin mil. USD$ Price per Sharein USD$ Employees 2005 5,341 722 6,133 44.554 2006 5,738 752 6,825 52.89 2007 6,283 890 7,329 63.81 2008 6,898 1,127 7,913 67.23 2009 6,987 1,232 9,305 58.34 2010 7,124 1,318 9,651 64.62 2011 7,584 1,271 10,430 70.38 2012 7,708 1,170 11,361 68.57 2013 8,054 1,293 12,149 90.12 29,979 2014 8,446 1,185 12,447 111.84 30,619 2015 10,282 695 26,478 137.28 49,517 2016 12,483 976 25,586 158.98 50,928 2017 12,093 1,030 37,734 192.11 41,933 2018 15,983 159 53,904 76,032 2019 17,290 1,082 51,765 76,093 2020 17,117 767 54,012 72,000 2021 20,248 2,002 53,866 75,000 Business segments[edit] A syringe made by BD Currently there are three business segments. BD Medical[edit] In certain places, BD Medical also offers consulting and analytics related services. BD Medical’s Consulting services are primarily targeted at hospitals, healthcare systems and networks of healthcare providers.[citation needed] BD Life Sciences[edit] Business units include Biosciences and Integrated Diagnostic Solutions.[citation needed] Offerings include preanalytical solutions for sample management; immunology research, including flow cytometry and multiomics tools; microbiology and molecular diagnostics; lab automation and informatics; and differentiated reagents and assays.[citation needed] BD Interventional[edit] The company’s line of plastic conical screwtop test tubes, known as ‘Falcon tubes’, is popular and the term is sometimes used as a generic term for such tubes.[11][12] Environmental and social track record[edit] As of February 2010, BD was ranked 18th in the EPA Fortune 500 List of Green Power Purchasers.[13] BD was also listed among the top 100 companies in Newsweek’s 2009 Green Rankings[14] ranking of the 500 largest American corporations based on environmental performance, policies, and reputation. BD placed third in the health care sector and 83rd overall.[15] In addition, BD has been a component of the Dow Jones Sustainability World Index and the Dow Jones Sustainability North America Index for the four and five consecutive years, respectively.[16] Pfitzer et al. (2013) identify BD’s development of a needleless injection system as an example of leading businesses’ role in creating shared value.[17] Health and safety issues[edit] In April 2016, the Occupational Safety and Health Administration fined BD US$112,700 for safety violations. They found repeat and serious violations of health and safety law that had resulted in two employees having partial finger amputations.[18][19] In 2020, C.R. Bard, Inc. and its parent company BD were fined $60 million USD for failing to adequately inform patients about health risks related to their transvaginal mesh devices.[20] Recalls[edit] 2007 Discardit II incident in Poland[edit] In mid-2007, the firm’s Discardit II series of syringes numbered 0607186 was withdrawn from hospitals and other medical services around Poland, about half a year after the discovery of remains of dark dust in some syringes, which were alleged to have been from this series. The newspaper Dziennik Online claimed that other series such as 06022444, 0603266, and 0607297 were also suspected of being contaminated. BD recalled and tested the syringes in question, and revealed sterile particulates in 0.013 percent of the products.[21] 2010 Q-Syte Luer and IV Catheter partial recall[edit] In February 2010 BD announced a voluntary product recall of certain lots of BD Q-Syte Luer Access Devices and BD Nexiva Closed IV Catheter Systems. BD stated that the use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death. The approximately 2.8 million BD Q-Syte and 2.9 million BD Nexiva units containing 5 million BD Q-Syte devices that were recalled were distributed in the United States, Asia, Canada, Europe, Mexico, the Middle East, South Africa, and South America. The recall was initiated on Oct. 28, 2009 after BD received complaints of problems due to air entry through a part of the device. BD stated that the cause of the problem was manufacturing deviation and claimed that it corrected the problem. BD announced that it notified customers about the recall by letter and has been working with the U.S. Food and Drug Administration and worldwide health agencies to coordinate recall activities.[22] 2021 IV Giving Sets[edit] In March 2021 BD announced a recall of infusion sets for CC, GP, VP, GW/GW800, SE, and IVAC 590 Alaris Pumps and gravity infusion sets and connectors following the news that a supplier falsified sterilisation documents going back ten years.[23][24] See also[edit] New Jersey portalCompanies portal Becton, Dickinson and Company headquarters List of biotech and pharmaceutical companies in the New York metropolitan area References[edit] ^ “Tom Polen”. bd.com. Retrieved 2 December 2021. ^ “Christopher R. Reidy”. bd.com. Retrieved 2 December 2021. ^ “Christopher DelOrefice”. bd.com. Retrieved 2 December 2021. ^ Jump up to: a b c d e f “Becton, Dickson and Company 2021 Annual Report”. investors.bd.com. 30 September 2021. Retrieved 22 February 2022. ^ “Fortune 500 List -2021”. Fortune Magazine. Fortune Media IP Limited. Retrieved 6 February 2022. ^ “Becton Dickinson to buy CareFusion for $12 billion in cash, stock”. Reuters. 2014-10-06. Retrieved 2021-12-10. ^ “Becton Dickinson to acquire Bard for $24 billion”. Reuters. 23 April 2017. ^ Walsh, Marsh (3 July 2004). “Syringe Manufacturer Settles Claim of Market Manipulation”. The New York Times. Retrieved 26 February 2019. ^ Perriello, Brad (5 December 2016). “UPDATE: Retractable Technologies plummets after appeals court tosses $352m win over Becton Dickinson”. Mass Device. Retrieved 27 February 2019. ^ “Becton Dickinson Revenue 2006–2018 | BDX”. www.macrotrends.net. Retrieved 2018-11-06. ^ Leslie DeLong; Nancy Burkhart (25 February 2013). General and Oral Pathology for the Dental Hygienist. Lippincott Williams & Wilkins. p. 663. ISBN 978-1-4511-3153-6. ^ Guide to Yeast Genetics and Molecular Biology: Volume 194: Guide to Yeast Genetics and Molecular Biology. Gulf Professional Publishing. 14 May 2004. p. 751. ISBN 978-0-08-057513-1. ^ “Green Power Purchasers Fortune 500 List”. Archived from the original on 2008-05-11. ^ “Newsweek, Greenest Big Companies in America – The 2009 List”. Archived from the original on 2009-09-24. ^ “Newsweek, Green Ranking 2009 – Becton Dickinson”. Archived from the original on 2009-09-26. ^ “Dow Jones Sustainability Indexes” (PDF). Archived from the original (PDF) on 2008-07-04. ^ Pfitzer, M., Bockstette, V. and Stamp, M., Innovating for Shared Value, Harvard Business Review, September 2013, accessed 24 July 2022 ^ “OSHA finds dozen violations at Becton, Dickinson and Co. in Holdrege after two workers suffer finger amputations”. OSHA. April 12, 2016. Retrieved April 18, 2016. ^ “Becton Dickinson dystrybutor – Sprzęt medyczny BD Medical Systems”. www.skamex.com.pl. Retrieved 2019-01-16. ^ “Company to pay $60 million for deceptive marketing with pelvic mesh – CBS News”. www.cbsnews.com. 25 September 2020. ^ “Reuters: Becton Dickinson expands syringe recall in Poland”. 2007-08-06. ^ “Reuters: Becton Dickinson recalls intravenous devices”. 2010-02-08. ^ “Millions of BD IV giving sets recalled amid contamination concerns”. NursingNotes. 2021-03-22. Retrieved 2021-05-27. ^ “National Patient Safety Alert: Supply disruption of sterile infusion sets and connectors manufactured by Becton Dickinson (BD) (NatPSA/2021/001/MHRA)”. GOV.UK. Retrieved 2021-05-27. External links[edit] Business data for Becton Dickinson: GoogleSEC filingsYahoo! Authority control databases International ISNI VIAF National Israel United States Czech Republic Other IdRef Retrieved from “https://en.wikipedia.org/w/index.php?title=BD_(company)&oldid=1178544523” Categories: BD (company)Companies listed on the New York Stock ExchangeMedical technology companies of the United StatesCompanies based in Bergen County, New Jersey1897 establishments in New JerseyHealth care companies established in 1897Franklin Lakes, New JerseyLife sciences industryTechnology companies established in 1897Health care companies based in New JerseyAmerican companies established in 1897Hidden categories: Wikipedia articles in need of updating from January 2022All Wikipedia articles in need of updatingArticles with short descriptionShort description is different from WikidataCoordinates not on WikidataAll articles with unsourced statementsArticles with unsourced statements from December 2021Articles with ISNI identifiersArticles with VIAF identifiersArticles with J9U identifiersArticles with LCCN identifiersArticles with NKC identifiersArticles with SUDOC identifiers This page was last edited on 4 October 2023, at 09:56 (UTC). Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization. Privacy policy About Wikipedia Disclaimers Contact Wikipedia Code of Conduct Developers Statistics Cookie statement Mobile view Toggle limited content width BD Regulatory Documents: BD (Becton Dickinson and Company)You need to enable JavaScript to run this app.English BD Worldwide×BD RegulatoryQuality CertificatesPosition StatementsSDS/Article StatementsResourcesFAQContact UsEnglishEnglish Français Español 日本語 Portuguese Deutsch 中文 한국어 BD WorldwideBD RegulatoryQuality CertificatesPosition StatementsSDS/Article StatementsResourcesFAQContact UsBD Regulatory DocumentsWelcome to the BD Regulatory Documents website.Use the tabs on the bottom to begin searching for BD Regulatory Documents.For assistance on how to search for BD Regulatory Documents, go to the bottom links and FAQ.Quality CertificatesPosition StatementsSDS/Article StatementsIn case you have questionsYou can use our links to How to Search for Quality Certificates? and How to Search for SDS/Article Statements? Or you can visit our FAQ section to follow up or you can also contact us to find out more.OfferingsCapabilitiesBrandsIntegrated solutionsCatalogsCompanyContact usCareersSustainabilitySuppliersNewsInvestorsVideo galleryClinical ExcellenceCase studiesConferences and symposiaWebcastsSupportTechnical supportCustomer portalsAlerts and noticesProduct security and privacy© 2020 BD. All rights reserved. Unless otherwise noted, BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company.Privacy|Terms & Conditions BD Completes Bard Acquisition, Creating New Global Health Care Leader – Dec 29, 2017 Products Solutions All Administrator Ambulatory Surgery Center Solutions Diagnostic Accuracy and Efficiency Hazardous Drug Safety Medication Management Solutions Patient Safety Solutions Sepsis Management Surgical Solutions Vascular Access Management (VAM) Clinician Ambulatory Surgery Center Solutions BD Original Equipment Manufacturing (OEM) Cervical Cancer Screening Portfolio Diagnostic Accuracy and Efficiency Hazardous Drug Safety Medication Management Solutions Patient Safety Solutions Sepsis Management Surgical Solutions Vascular Access Management (VAM) Distributor BD Original Equipment Manufacturing (OEM) Drug Development Company Drug Delivery Systems Medical Device Manufacturer BD Original Equipment Manufacturing (OEM) Laboratory BD Original Equipment Manufacturing (OEM) Cervical Cancer Screening Portfolio Diagnostic Accuracy and Efficiency Patient Safety Solutions Sepsis Management Traditional Microbiology Pharmacy Hazardous Drug Safety Patient Safety Solutions Medication Management Solutions Sepsis Management Vascular Access Management (VAM) Surgery Ambulatory Surgery Center Solutions Patient Safety Solutions Surgical Solutions Venous technology COVID-19 Response COVID-19 Tests and Vaccine Preparedness At-Home Test Rapid COVID-19 Testing COVID-19 PCR Testing Vaccine Preparedness COVID-19 Response Plan Overview Our Responsibility in Time of Crisis Patient Care Support Across the Continuum COVID-19 Tools and Trainings Product Manual Inventory Allocation COVID-19 Insights and Analytics Infection Control Training COVID-19 Support Offerings Biosciences Solutions Medication Management Solutions Vascular Access and Medication Delivery Knowledge Center Events Literature Training Support About BD Our Company About Us Segments Leadership Ethics and Compliance Cybersecurity at BD About Us Trust Center Bulletins and Patches Disclosure Process Helpful Resources Distributors Distributor List Unique device identifier (UDI) ESG (Environmental, Social, and Governance) Global Health Inclusion and Diversity Sustainability Social Investing Global External Funding Opportunities Overview Charitable Contributions Commercial sponsorships Educational grants Investigator sponsored studies Investors Innovation at BD Overview BD Idea Submission Process Smart Connected Care New Care Settings Chronic Disease Outcomes News, Media and Blogs Policies, Guidelines and Statements Center Quality Recent Mergers and Acquisitions Suppliers Corporate Policies and Expectations Doing Business with BD Global Procurement Supplier Programs Careers United States North America Canada (FR) Canada (EN) Mexico United States South America Argentina Brasil Chile Colombia Europe Belgium (FR) Belgium (NL) Česká republika Denmark Europe Suomi France Deutschland Hungary (EN) Hungary (HU) United Kingdom Ireland Italia Nederland Norge Polska Россия España Sverige Schweiz Türkiye United Kingdom Middle East / Africa Middle East, North Africa Africa Asia / Pacific Australia / New Zealand 中国 India Indonesia 日本 Korea Malaysia Philippines Singapore Thailand Vietnam Login United States North America Canada (FR) Canada (EN) Mexico United States South America Argentina Brasil Chile Colombia Europe Belgium (FR) Belgium (NL) Česká republika Denmark Europe Suomi France Deutschland Hungary (EN) Hungary (HU) United Kingdom Ireland Italia Nederland Norge Polska Россия España Sverige Schweiz Türkiye United Kingdom Middle East / Africa Middle East, North Africa Africa Asia / Pacific Australia / New Zealand 中国 India Indonesia 日本 Korea Malaysia Philippines Singapore Thailand Vietnam Login MediaRoom News and media BD blog Press releases ESG news Executive leadership In the news Awards Media contacts BD Completes Bard Acquisition, Creating New Global Health Care Leader PR Newswire FRANKLIN LAKES, N.J., Dec. 29, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of C. R. Bard, Inc. (NYSE: BCR), creating a new health care industry leader with approximately $16 billion in annualized revenue. The combined company is uniquely positioned to improve both the treatment of disease for patients and the process of care for health care providers. The transaction builds on BD’s leadership in medication management and infection prevention with an expanded offering of solutions across the care continuum. Additionally, Bard’s strong product portfolio and innovation pipeline will increase BD’s opportunities in fast-growing clinical areas, and the combination will enhance growth opportunities for the combined company in non-U.S. markets. “Today is a historic day for BD as we welcome Bard and its 16,000 associates to BD,” said Vincent A. Forlenza, chairman and CEO. “These companies each have a legacy of more than 100 years of advancing the world of health and supporting those on the frontlines of health care. We look forward to continuing to lead the industry through innovation and partnerships that bring more valuable solutions to our customers and their patients.” Under the terms of the transaction, upon completion of the acquisition, Bard became a wholly owned subsidiary of BD, and each outstanding share of Bard common stock was converted to the right to receive (1) $222.93 in cash without interest and (2) 0.5077 of a share of BD common stock. As a result of the completion of the acquisition, Bard shares will cease trading and will be delisted from the New York Stock Exchange. Excluding transaction-related expenses, BD does not expect the acquisition to have a material impact on the company’s financial results in the first quarter of fiscal 2018, which ends on Dec. 31, 2017. The company continues to expect the transaction to generate low-single digit accretion to adjusted earnings per share in fiscal year 2018, and high-single digit accretion in fiscal year 2019. The company will provide an update to its full fiscal year 2018 outlook on its first fiscal quarter earnings conference call to reflect the anticipated contribution from Bard’s operations through BD’s fiscal year, which ends Sept. 30, 2018. Beginning with the second quarter of fiscal 2018, BD will report a new Interventional segment structure, which will include a majority of Bard offerings, with the remainder being reported under the Medical segment. For more detailed information on BD’s reporting changes, please refer to the BD Reporting Changes slide presentation available on BD’s website at www.bd.com/investors. Information for Bard Shareholders BD has appointed Computershare Trust Company N.A. as paying agent for payment of the merger consideration described above. For Bard registered shareholders who hold Bard stock certificates or a mix of Bard stock certificates and book-entry shares, information concerning the exchange of Bard shares for the per share merger consideration is being mailed to the holder of record of the certificated Bard shares. This information will outline the steps to be taken to obtain the merger consideration. These registered shareholders do not need to take any action regarding their shares until contacted by the paying agent. For Bard registered shareholders who hold Bard stock solely in book-entry format, Computershare Trust Company N.A. will debit all book-entry Bard shares in the accounts of holders of record, credit the appropriate number of book-entry BD shares to each holder, and make payment of the cash consideration (less any applicable tax withholding) by mailing a check representing such amount to each such holder. For additional information, please contact Computershare Trust Company, N.A. at (877) 498-8861 (within the United States, its territories and Canada) or +1 (781) 575-2879 (outside the United States, its territories and Canada). Bard shareholders who own shares through a bank, brokerage firm or other nominee (in “street name”), should contact their bank, broker or nominee for further information about receiving the merger consideration. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to better diagnose disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com. FORWARD-LOOKING STATEMENTS This press release contains certain estimates and other “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward looking statements generally are accompanied by words such as “will”, “expect”, “outlook” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” or other similar words, phrases or expressions and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements regarding the estimated or anticipated future results of the combined company, the anticipated benefits of the combination and other statements that are not historical facts. These statements are based on the current expectations of BD management and are not predictions of actual performance. These statements are subject to a number of risks and uncertainties regarding BD and Bard’s respective businesses and the acquisition, and actual results may differ materially. These risks and uncertainties include, but are not limited to, (i) risks relating to the integration of Bard’s operations, products and employees into BD and the possibility that the anticipated synergies and other benefits of the proposed acquisition will not be realized or will not be realized within the expected timeframe, (ii) the outcome of any legal proceedings related to the proposed acquisition, (iii) the ability to market and sell Bard’s products in new markets, including the ability to obtain necessary regulatory product registrations and clearances, (iv) the impact of the additional debt BD incurred and the equity and equity-linked securities that BD issued to finance the acquisition, including BD’s credit ratings and cost of borrowing, and BD’s ability to access available financing, including for the refinancing of BD’s or Bard’s debt on a timely basis and reasonable terms, (v) the loss of key senior management or other associates; (vi) the anticipated demand for BD’s and Bard’s products, including the risk of future reductions in government healthcare funding, changes in reimbursement rates or changes in healthcare practices that could result in lower utilization rates or pricing pressures, (vii) the impact of competition in the medical device industry, (viii) the risks of fluctuations in interest or foreign currency exchange rates, (ix) product liability claims, (x) difficulties inherent in product development, including the timing or outcome of product development efforts, the ability to obtain regulatory approvals and clearances and the timing and market success of product launches, (xi) risks relating to fluctuations in the cost and availability of raw materials and other sourced products and the ability to maintain favorable supplier arrangements and relationships, (xii) successful compliance with governmental regulations applicable to the combined company, (xiii) changes in regional, national or foreign economic conditions, (xiv) uncertainties of litigation, and (xv) other factors discussed in BD’s and Bard’s respective filings with the Securities and Exchange Commission. The forward-looking statements in this document speak only as of the date of this document. BD undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by applicable laws or regulations. Contacts: Troy Kirkpatrick Monique N. Dolecki BD Public Relations BD Investor Relations 858.617.2361 201.847.5378 [email protected] [email protected] View original content with multimedia:http://www.prnewswire.com/news-releases/bd-completes-bard-acquisition-creating-new-global-health-care-leader-300576098.html SOURCE BD (Becton, Dickinson and Company) Follow us Quick Links Alerts and Notices Careers Cybersecurity Electronic Instructions for Use Events Investors Inclusion and Diversity Literature News, Media and Blogs Our Company Support Training © 2022 BD. All rights reserved. BD and the BD Logo are trademarks of Becton, Dickinson and Company. All other trademarks are the property of their respective owners. Contact us Cookie Preferences Privacy Terms of Use Website Accessibility Becton, Dickinson and Company | LinkedIn Skip to main content LinkedIn Articles People Learning Jobs Join now Sign in Becton, Dickinson and Company Medical Equipment Manufacturing BD is the world’s largest manufacturer and seller of medical equipment. Follow View all 397 employees Report this company About us BD is one of the world’s largest medical technology companies that produce and sell medical equipment, medical systems and reagents, dedicated to improving human health around the world. BD focuses on improving drug treatment, improving the quality and speed of diagnosis of infectious diseases, and promoting the research and discovery of new drugs and vaccines. BD has strong research and development capabilities to fight many of the world’s most intractable diseases. Founded in New York in 1897, the company is headquartered in Franklin Lake, New Jersey, USA and employs more than 25000 people in about 50 countries around the world. The company’s clients include medical institutions, life sciences research institutes, clinical laboratories, industrial units and the general public. Industry Medical Equipment Manufacturing Company size 501-1,000 employees Headquarters 纽约 Type Public Company Locations Primary 纽约, 10001, US Get directions Employees at Becton, Dickinson and Company Victor Montijo Lena Lee International trade in cosmetics and medical devices Vishal Lokhande Program Manager, PMO, R&D at Becton Dickinson and Company – BD Biosciences See all employees Similar pages BD Medical Equipment Manufacturing Franklin Lakes, New Jersey Becton Dickinson Company (Safety Syringes, Inc. ) Medical Equipment Manufacturing San Diego, CA Fresenius Medical Care Hospitals and Health Care Bad Homburg, Frankfurt Cardinal Health Hospitals and Health Care Dublin, OH Stryker Medical Equipment Manufacturing Kalamazoo, MI Medtronic Medical Equipment Manufacturing Minneapolis, MN Abbott Hospitals and Health Care Abbott Park, Illinois Johnson & Johnson Hospitals and Health Care New Brunswick, NJ GE HealthCare Hospitals and Health Care Philips Hospitals and Health Care Amsterdam, Noord-Holland Show more similar pages Show fewer similar pages Browse jobs Cyber Security Specialist jobs 31,368 open jobs Analyst jobs 760,055 open jobs Field Engineer jobs 90,104 open jobs Senior Executive jobs 180,925 open jobs Senior Associate jobs 131,985 open jobs Embedded Software Engineer jobs 8,705 open jobs Office Manager jobs 173,544 open jobs Associate jobs 1,094,512 open jobs Intern jobs 48,214 open jobs Manager jobs 2,003,890 open jobs Assistant Manager jobs 359,689 open jobs Quality Assurance Specialist jobs 15,308 open jobs Clinical Research Associate jobs 15,912 open jobs Engineer jobs 608,159 open jobs Project Manager jobs 312,603 open jobs Product Specialist jobs 89,542 open jobs Commercial Director jobs 67,208 open jobs Sales Executive jobs 145,700 open jobs Executive jobs 700,389 open jobs Specialist jobs 849,142 open jobs Show more jobs like this Show fewer jobs like this More searches More searches Engineer jobs Manager jobs Product Specialist jobs Sales Executive jobs LinkedIn © 2023 About Accessibility User Agreement Privacy Policy Your California Privacy Choices Cookie Policy Copyright Policy Brand Policy Guest Controls Community Guidelines العربية (Arabic) Čeština (Czech) Dansk (Danish) Deutsch (German) English (English) Español (Spanish) Français (French) हिंदी (Hindi) Bahasa Indonesia (Indonesian) Italiano (Italian) 日本語 (Japanese) 한국어 (Korean) Bahasa Malaysia (Malay) Nederlands (Dutch) Norsk (Norwegian) Polski (Polish) Português (Portuguese) Română (Romanian) Русский (Russian) Svenska (Swedish) ภาษาไทย (Thai) Tagalog (Tagalog) Türkçe (Turkish) Українська (Ukrainian) 简体中文 (Chinese (Simplified)) 正體中文 (Chinese (Traditional)) Language Agree & Join LinkedIn By clicking Continue, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy. Sign in to see who you already know at Becton, Dickinson and Company Sign in Welcome back Email or phone Password Show Forgot password? Sign in or By clicking Continue, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy. New to LinkedIn? Join now or By clicking Continue, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy. New to LinkedIn? Join now Join to see who you already know at Becton, Dickinson and Company Join now Sign in Becton Dickinson and Co (BDX) Stock Price & News – Google FinanceFinanceFinanceSign inFinancefinance_modeHomemanage_searchMarket trendsPortfoliosaddCreate portfolioWatchlistsaddCreate watchlistMost ActiveMarathon Digital Holdings Inc-16.44%Tesla Inc-1.86%Nio Inc – ADR-3.82%Advanced Micro Devices, Inc.-0.91%Riot Platforms Inc-12.10%DISH Network Corp+1.94%settingsSettingsfeedbackSend feedbackMarketsUSEuropeAsiaCurrenciesCryptoFuturesS&P 500 falls slightly Friday, but rides 9-week win streak to end 2023 with 24% gain: Live updates• CNBC• 4 hours agoDow Jones37,689.54-0.055%-20.56Dow Jones37,689.540.055%S&P 5004,769.83-0.28%-13.52S&P 5004,769.830.28%Nasdaq15,011.35-0.56%-83.78Nasdaq15,011.350.56%Russell2,027.07-1.52%-31.26Russell2,027.071.52%VIX12.45-0.16%-0.020VIX12.450.16%HomeBDX • NYSEBecton Dickinson and CoFollowShare$243.83After Hours:$243.83(0.00%)0.00Closed: Dec 29, 6:11:45 PM GMT-5 · USD · NYSE · Disclaimer1D5D1M6MYTD1Y5YMAXinsightsKey eventsKey events shows relevant news articles on days with large price movementsKey eventsKey events shows relevant news articles on days with large price movementsKey eventsarrow_forward_iosKey events shows relevant news articles on days with large price movementsNo dataclosesearchCompare toAbbott Laboratories$110.07ABT0.30%Johnson & Johnson$156.74JNJ0.10%Cencora Inc$205.38COR0.93%Danaher Corporation$231.34DHR0.77%Medtronic PLC$82.38MDT0.42%Merck & Co Inc$109.02MRK0.23%PepsiCo, Inc.$169.84PEP0.27%Intuitive Surgical, Inc.$337.36ISRG0.30%Amgen, Inc.$288.02AMGN0.15%Stryker Corp$299.46SYK0.11%In the newsMarketWatch2 days agoBecton Dickinson & Co. stock underperforms Wednesday when compared to competitorsSimply Wall St1 day agoBecton, Dickinson and Company’s (NYSE:BDX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?Medical Design & Outsourcing1 week agoBD pay increases for CEO Tom Polen and the median employeeFinancialsIncome StatementQuarterlyAnnualSep 2023Jun 2023Mar 2023Dec 2022Sep 2022RevenueNet income(USD)Sep 2023infoFiscal Q4 2023 ended 9/30/23. Reported on 11/9/23.Y/Y changeRevenueThe total amount of income generated by the sale of goods or services related to the company’s primary operations5.09B6.85%Operating expenseRepresents the total incurred expenses through normal operations1.21B-21.57%Net incomeCompany’s earnings for a period net of operating costs, taxes, and interest108.00M-62.50%Net profit marginMeasures how much net income or profit is generated as a percentage of revenue.2.12-64.96%Earnings per shareRepresents the company’s profit divided by the outstanding shares of its common stock.3.4224.36%EBITDAEarnings before interest, taxes, depreciation, and amortization, is a measure of a company’s overall financial performance and is used as an alternative to net income in some circumstances1.64B41.87%Effective tax rateThe percent of their income that a corporation pays in taxes14.92%—Balance SheetQuarterlyAnnualSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Total assetsTotal liabilities(USD)Sep 2023infoFiscal Q4 2023 ended 9/30/23. Reported on 11/9/23.Y/Y changeCash and short-term investmentsInvestments that are relatively liquid and have maturities between 3 months and one year1.42B40.43%Total assetsThe total amount of assets owned by a company52.78B-0.29%Total liabilitiesSum of the combined debts a company owes26.98B-2.42%Total equityThe value of subtracting the total liabilities from the total assets of a company25.80B—Shares outstandingTotal number of common shares outstanding as of the latest date disclosed in a financial filing290.41M—Price to bookA ratio used to determine if a company’s market value is in line with the value of its assets less liabilities and preferred stock2.74—Return on assetsA financial ratio that shows a company’s profitability compared to its assets4.98%—Return on capitalCompany’s return above the average cost it pays for its debt and equity capital6.20%—Cash FlowQuarterlyAnnualSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Net change in cash(USD)Sep 2023infoFiscal Q4 2023 ended 9/30/23. Reported on 11/9/23.Y/Y changeNet incomeCompany’s earnings for a period net of operating costs, taxes, and interest108.00M-62.50%Cash from operationsNet cash used or generated for core business activities——Cash from investingNet cash used or generated in investing activities such as purchasing assets——Cash from financingNet cash used or generated in financing activities such as dividend payments and loans——Net change in cashThe amount by which a company’s cash balance increases or decreases in an accounting period——Free cash flowAmount of cash a business has after it has met its financial obligations such as debt and outstanding payments——StockOwnership of a fraction of a corporation and the right to claim a share of the corporation’s assets and profits equal to the amount of stock ownedUS listed securityListed on NYSEUS headquarteredHeadquartered in Franklin Lakes, New Jersey, United StatesPrevious closeThe last closing price$243.03Day rangeThe range between the high and low prices over the past day$242.37 – $244.13Year rangeThe range between the high and low prices over the past 52 weeks$228.62 – $287.32Market capA valuation method that multiplies the price of a company’s stock by the total number of outstanding shares.70.60B USDAvg VolumeThe average number of shares traded each day over the past 30 days1.86MP/E ratioThe ratio of current share price to trailing twelve month EPS that signals if the price is high or low compared to other stocks47.84Dividend yieldThe ratio of annual dividend to current share price that estimates the dividend return of a stock1.56%Primary exchangeListed exchange for this securityNYSECDP Climate Change ScoreA score provided by CDP (formerly the Carbon Disclosure Project) that rates a company on its climate transparency and performanceBAboutBecton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies. BD is ranked #177 in the 2021 Fortune 500 list based on its revenues for the fiscal year ending September 30, 2020. In October 2014, the company agreed to acquire CareFusion for a price of US$12.2 billion in cash and stock. In April 2017, C. R. Bard announced that it would be acquired by Becton, Dickinson and Company. The transaction was completed later that year, and the company became a wholly-owned subsidiary of BD, rebranded as Bard. WikipediaCEOThomas PolenFounded1897HeadquartersFranklin Lakes, New JerseyUnited StatesWebsitebd.comEmployees73,000Discover moreYou may be interested ininfoThis list is generated from recent searches, followed securities, and other activity. Learn moreAll data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn moreIndexDow Jones Industrial Average37,689.540.055%add_circle_outlineIndexS&P 5004,769.830.28%add_circle_outlineTSLATesla Inc$248.481.86%add_circle_outlineAAPLApple Inc$192.530.54%add_circle_outlineAMZNAmazon.com Inc$151.940.94%add_circle_outlineBABAAlibaba Group Holding Ltd – ADR$77.510.35%add_circle_outlineFFord Motor Co$12.191.22%add_circle_outlineNXSTNexstar Media Group Inc$156.751.33%add_circle_outlineBABoeing Co$260.660.12%add_circle_outlineIndexNasdaq Composite15,011.350.56%add_circle_outlineIndexVIX12.450.16%add_circle_outlineMSFTMicrosoft Corp$376.040.20%add_circle_outlineTAT&T Inc.$16.780.18%add_circle_outlineCCLCarnival Corp$18.540.70%add_circle_outlineDISWalt Disney Co$90.290.12%add_circle_outlineSPYSPDR S&P 500 ETF Trust$475.310.29%add_circle_outlineWMTWalmart Inc$157.650.0032%add_circle_outlineNFLXNetflix Inc$486.880.74%add_circle_outlinePeople also search forABTAbbott Laboratories$110.070.30%add_circle_outlineJNJJohnson & Johnson$156.740.10%add_circle_outlineCORCencora Inc$205.380.93%add_circle_outlineDHRDanaher Corporation$231.340.77%add_circle_outlineMDTMedtronic PLC$82.380.42%add_circle_outlineMRKMerck & Co Inc$109.020.23%add_circle_outlinePEPPepsiCo, Inc.$169.840.27%add_circle_outlineISRGIntuitive Surgical, Inc.$337.360.30%add_circle_outlineAMGNAmgen, Inc.$288.020.15%add_circle_outlineSYKStryker Corp$299.460.11%add_circle_outlineTMOThermo Fisher Scientific Inc$530.790.46%add_circle_outlineABBVAbbVie Inc$154.970.14%add_circle_outlineLLYEli Lilly And Co$582.920.36%add_circle_outlineBSXBoston Scientific Corporation$57.812.72%add_circle_outlineWMTWalmart Inc$157.650.0032%add_circle_outlineMMM3M Co$109.320.34%add_circle_outlineCHDChurch & Dwight Co., Inc.$94.560.61%add_circle_outlineCMSCMS Energy Corporation$58.070.12%add_circle_outlineHelpSend feedbackPrivacyTermsDisclaimerSearchClear searchClose searchMain menuGoogle apps BD Selects “embecta” as Name of New Company for Planned Spinoff of Diabetes Care Business; Announces Remainder of Leadership Team – Dec 6, 2021 Products Solutions All Administrator Ambulatory Surgery Center Solutions Diagnostic Accuracy and Efficiency Hazardous Drug Safety Medication Management Solutions Patient Safety Solutions Sepsis Management Surgical Solutions Vascular Access Management (VAM) Clinician Ambulatory Surgery Center Solutions BD Original Equipment Manufacturing (OEM) Cervical Cancer Screening Portfolio Diagnostic Accuracy and Efficiency Hazardous Drug Safety Medication Management Solutions Patient Safety Solutions Sepsis Management Surgical Solutions Vascular Access Management (VAM) Distributor BD Original Equipment Manufacturing (OEM) Drug Development Company Drug Delivery Systems Medical Device Manufacturer BD Original Equipment Manufacturing (OEM) Laboratory BD Original Equipment Manufacturing (OEM) Cervical Cancer Screening Portfolio Diagnostic Accuracy and Efficiency Patient Safety Solutions Sepsis Management Traditional Microbiology Pharmacy Hazardous Drug Safety Patient Safety Solutions Medication Management Solutions Sepsis Management Vascular Access Management (VAM) Surgery Ambulatory Surgery Center Solutions Patient Safety Solutions Surgical Solutions Venous technology COVID-19 Response COVID-19 Tests and Vaccine Preparedness At-Home Test Rapid COVID-19 Testing COVID-19 PCR Testing Vaccine Preparedness COVID-19 Response Plan Overview Our Responsibility in Time of Crisis Patient Care Support Across the Continuum COVID-19 Tools and Trainings Product Manual Inventory Allocation COVID-19 Insights and Analytics Infection Control Training COVID-19 Support Offerings Biosciences Solutions Medication Management Solutions Vascular Access and Medication Delivery Knowledge Center Events Literature Training Support About BD Our Company About Us Segments Leadership Ethics and Compliance Cybersecurity at BD About Us Trust Center Bulletins and Patches Disclosure Process Helpful Resources Distributors Distributor List Unique device identifier (UDI) ESG (Environmental, Social, and Governance) Global Health Inclusion and Diversity Sustainability Social Investing Global External Funding Opportunities Overview Charitable Contributions Commercial sponsorships Educational grants Investigator sponsored studies Investors Innovation at BD Overview BD Idea Submission Process Smart Connected Care New Care Settings Chronic Disease Outcomes News, Media and Blogs Policies, Guidelines and Statements Center Quality Recent Mergers and Acquisitions Suppliers Corporate Policies and Expectations Doing Business with BD Global Procurement Supplier Programs Careers United States North America Canada (FR) Canada (EN) Mexico United States South America Argentina Brasil Chile Colombia Europe Belgium (FR) Belgium (NL) Česká republika Denmark Europe Suomi France Deutschland Hungary (EN) Hungary (HU) United Kingdom Ireland Italia Nederland Norge Polska Россия España Sverige Schweiz Türkiye United Kingdom Middle East / Africa Middle East, North Africa Africa Asia / Pacific Australia / New Zealand 中国 India Indonesia 日本 Korea Malaysia Philippines Singapore Thailand Vietnam Login United States North America Canada (FR) Canada (EN) Mexico United States South America Argentina Brasil Chile Colombia Europe Belgium (FR) Belgium (NL) Česká republika Denmark Europe Suomi France Deutschland Hungary (EN) Hungary (HU) United Kingdom Ireland Italia Nederland Norge Polska Россия España Sverige Schweiz Türkiye United Kingdom Middle East / Africa Middle East, North Africa Africa Asia / Pacific Australia / New Zealand 中国 India Indonesia 日本 Korea Malaysia Philippines Singapore Thailand Vietnam Login MediaRoom News and media BD blog Press releases ESG news Executive leadership In the news Awards Media contacts BD Selects “embecta” as Name of New Company for Planned Spinoff of Diabetes Care Business; Announces Remainder of Leadership Team FRANKLIN LAKES, N.J., Dec. 6, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that “embecta” [pronounced em-BECK-tah] will be the name of the independent, publicly-traded company that will hold BD’s Diabetes Care business upon the completion of the previously announced spinoff, which is expected to close in the second quarter of calendar year 2022. The name “embecta” represents the future company’s commitment to people living with diabetes and its corporate heritage: the “em-” prefix evokes empathy for people living with diabetes and the empowerment of the new company and its global team to seek new avenues of growth, and the “bect” embodies the BD spirit by embedding part of the legacy brand — the “bect” from Becton, Dickinson and Company — in the name. The logo consists of two bold curved lines, fused together to form a circle around a single point, which symbolizes the concept of bringing people together to form a collaborative, personal relationship and creates a strong connection with the BD visual identity. Embecta Download: Hi Res Loading…Previous ItemNext Item View File Download File Embecta Play File embecta-Brand-Reveal “The Diabetes Care business can trace its roots back nearly 100 years to BD’s introduction of the world’s first specialized insulin syringe in 1924 and today is the leading producer of diabetes injection devices in the world,” said Tom Polen, chairman, CEO and president of BD. “We’re proud to see that shared legacy reflected in the new name.” Devdatt (Dev) Kurdikar, worldwide president of BD Diabetes Care, who will become CEO of embecta upon completion of the spinoff said, “The Diabetes Care business is the trusted partner our customers and people living with diabetes have known for nearly a century, now with a single focus and the financial flexibility to pursue organic and inorganic innovations that will give more people a better life. We have assembled a diverse and experienced leadership team that is excited about the possibilities ahead, and our global team is passionate about the profound impact they can have on the growing number of people who live with this chronic and prevalent disease. Together, we look forward to making embecta synonymous with a life unlimited by diabetes.” Leadership TeamUpon completion of the spinoff, embecta will have an experienced leadership team led by Dev Kurdikar, each bringing deep and relevant experience in the medical technology industry: Ginny Blocki will serve as senior vice president, product management and global marketing. Blocki joined BD as senior vice president and head of global marketing and product management for Diabetes Care in October 2021. Previously, she was head of U.S. medication delivery marketing for Baxter and before that held leadership roles with Assertio Therapeutics, Abbott Laboratories, Baxter and Baxalta. She has a Bachelor of Science degree in finance from Indiana University and completed the Executive Scholar Program in General Management at Kellogg School of Management, Northwestern University. Tom Blount will serve as senior vice president and president, North America. Blount joined BD in 2016 and has served as vice president and general manager, U.S. Diabetes Care, since May 2020. Previously, he spent 16 years in roles of increasing leadership responsibility at Sanofi following five years on active duty in the U.S. Army. He holds a Bachelor of Science degree in German/French from the United States Military Academy at West Point and a Master of Science in International Relations from Troy University – European Campus. Shaun Curtis will serve as senior vice president, global manufacturing and supply chain. Curtis joined BD in 2004 and has served as the worldwide vice president of operations for Diabetes Care since 2018. Previously, he was manufacturing director at BD Plymouth in the U.K. He holds a Master of Business Administration with distinction from Northampton University, U.K. He earned an Honors Degree in mechanical engineering from Plymouth University and achieved a Higher National Diploma in mechanical engineering with distinction at Swindon College. As previously announced, Jake Elguicze will serve as senior vice president and chief financial officer. Elguicze joined BD in May 2021 as the senior vice president, finance, of the Diabetes Care business. Previously, he served as treasurer and head of investor relations for Teleflex, which he joined in 2006 following eight years at Motorola in operating finance roles. He has a Bachelor of Science in accounting from the University of Scranton and a Master of Business Administration in finance from St. Joseph’s University. Ajay Kumar will serve as senior vice president and chief human resources officer. Kumar joined BD in 2007 and currently serves as vice president, human resources, for the Diabetes Care business. In his time at BD, he has also held leadership roles as vice president, human resources for the Medication Delivery Systems and Diagnostic Systems businesses, and led talent management for BD Greater Asia. Previously, he spent 13 years with Unilever India, where he held positions of increasing responsibility across all aspects of HR. He holds a degree in mechanical engineering from Birla Institute of Technology Mesra and a Master of Business Administration in HR from XLRI Jamshedpur. As previously announced, Devdatt (Dev) Kurdikar will serve as chief executive officer. Kurdikar has served as worldwide president of Diabetes Care at BD since February 2021. Previously, he was president and CEO of Cardiac Science Corporation. Prior to that, he was vice president and general manager, Men’s Health at Boston Scientific Corp. and held the same role at American Medical Systems, leading the business through its integration into BSC. He also held leadership roles of increasing responsibility in finance, strategy and integration, R&D planning and operations over the course of 11 years at Baxter International. Kurdikar holds a Bachelor of Science in chemical engineering from the University of Bombay in India, a Master of Science in chemical engineering from Washington State University, a Ph.D. in chemical engineering from Purdue University and a Master of Business Administration from Washington University in St. Louis. Jeff Mann will serve as senior vice president, general counsel and head of corporate development. Mann joined BD in August 2021 after serving as general counsel and corporate secretary of Cantel Medical Corp. Prior to Cantel, he spent 14 years with Boston Scientific Corporation. He holds a Bachelor of Science in civil and environmental engineering from Lafayette College and a law degree from Boston College Law School, magna cum laude. Slobodan Radumilo will serve as senior vice president and president, international. Radumilo joined BD in 2016 as vice president and general manager of Diabetes Care for BD in the EMEA region. Previously, he held roles of increasing responsibility at Medtronic from 1997 to 2016, most recently as vice president of neuromodulation for Europe and Canada, regional vice president for Central and Eastern Europe and Central Asia, and regional vice president for Central and Eastern Europe, Greece and Israel. He holds a Bachelor of Science degree in electrical engineering, a Master of Science degree in biomedical engineering and a Diploma in Management from the University of Zagreb in Croatia, as well as a Diploma in Leadership from the Glasgow Caledonian University. Colleen Riley will serve as senior vice president and chief technology officer. Riley joined BD as senior vice president, chief technology officer for the Diabetes Care business in October 2021. Prior to that, she was the senior vice president of innovation and development for Terumo Blood and Cell Technologies and previously served in leadership roles at Stryker Orthopedics, Novartis AG, Nexis Vision Inc. and J&J. She has a Bachelor of Arts in chemistry, a Master of Science in physiological optics and a Doctor of Optometry degree from Indiana University.Spinoff is expected to be completed in the second quarter of calendar year 2022 BD expects the spinoff to be completed in the second quarter of calendar year 2022, subject to the final approval of the BD Board of Directors and the effectiveness of a Registration Statement on Form 10 to be filed with the U.S. Securities and Exchange Commission (SEC). About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo. Forward-Looking Statements This press release contains certain forward-looking statements (as defined under Federal securities laws) regarding BD and the proposed spinoff of its Diabetes Care business, including the anticipated benefits of the spinoff and the expected timing of completion of the spinoff. All such statements are based upon current expectations of BD and involve a number of risks and uncertainties. With respect to forward-looking statements contained herein, a number of factors could cause actual outcomes to vary materially. These factors include, but are not limited to, risks relating to the impact of the COVID-19 pandemic; product efficacy or safety concerns resulting in product recalls or other actions; new or changing laws and regulations (including the imposition of tariffs or changes in laws impacting international trade) or changes in enforcement practices with respect to such laws; fluctuations in costs and availability of raw materials or adverse changes in supplier or customer arrangements and relationships; legislative or regulatory changes to the U.S. or foreign health care systems, potential cuts in governmental health care spending, or governmental or private measures to contain health care costs, including changes in pricing and reimbursement policies reduce demand or downward pricing pressure; changes in interest or foreign currency exchange rates; adverse changes in regional, national or foreign economic conditions, particularly in emerging markets, including any impact on access to credit markets, product demand or our supply chain; the adverse impact of cyber-attacks impacting information systems or products; competitive factors including technological advances and new products introduced by competitors; supply chain interruptions or interruptions in manufacturing or sterilization processes; pricing and market pressures; difficulties inherent in product development, delays in product introductions and uncertainty of market acceptance of new products; adverse changes in geopolitical conditions; increases in energy costs and their effect on, among other things, the cost of producing products; the ability to successfully integrate any acquired businesses; uncertainties of litigation; issuance of new or revised accounting standards; risks associated with the impact, timing or terms of the spinoff; risks associated with the expected benefits and costs of the spinoff, including the risk that the expected benefits of the spinoff will not be realized within the expected time frame, in full or at all, and the risk that conditions to the spinoff will not be satisfied and/or that the spinoff will not be completed within the expected time frame, on the expected terms or at all; the expected qualification of the spinoff as a tax-free transaction for U.S. federal income tax purposes, including whether or not an IRS ruling will be sought or obtained; risks associated with expected financing transactions undertaken in connection with the spinoff and risks associated with indebtedness incurred in connection with the spinoff; the risk that dis-synergy costs, costs of restructuring transactions and other costs incurred in connection with the spinoff will exceed our estimates; and the impact of the spinoff on our businesses and the risk that the spinoff may be more difficult, time-consuming or costly than expected, including the impact on our resources, systems, procedures and controls, diversion of management’s attention and the impact on relationships with customers, suppliers, employees and other business counterparties, as well as other factors discussed in BD’s filings with the SEC. There can be no assurance that BD’s spinoff will in fact be completed in the manner described or at all. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations. Contacts: Media: Investors: Troy Kirkpatrick Nadia Goncalves VP, Public Relations Senior Director, Investor Relations 858.617.2361 201.847.5934 [email protected] [email protected] SOURCE BD (Becton, Dickinson and Company) Follow us Quick Links Alerts and Notices Careers Cybersecurity Electronic Instructions for Use Events Investors Inclusion and Diversity Literature News, Media and Blogs Our Company Support Training © 2022 BD. All rights reserved. BD and the BD Logo are trademarks of Becton, Dickinson and Company. All other trademarks are the property of their respective owners. Contact us Cookie Preferences Privacy Terms of Use Website Accessibility

Leave a Comment